Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00348023 · ClinicalTrials.gov registry record · Phase 4
Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension
A Phase 4 study, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00348023: Completed Phase 4 study, sponsored by Innovative Medical.
NCT00348023 is a Phase 4 study that has completed, run by Innovative Medical. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00348023, a Phase 4 study, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.
Interventions
- DRUG Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 4 |
What the finished NCT00348023 record still lists
NCT00348023 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5% is the first listed.
NCT00348023 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00348023 about?
NCT00348023 is a clinical study titled "Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension". Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.
What is the current status of trial NCT00348023?
This trial is currently completed. It is a Phase 4 study.
What interventions are being tested in trial NCT00348023?
The interventions under investigation include: Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5% (DRUG).
Who is sponsoring clinical trial NCT00348023?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.